Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies
Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.
Published on the 10th of october 2023. Read the full news report following this link.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2024). Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/11osy





